Objectives: High-dose penicillin therapy is effective in approximately 90% of pneumococcal pneumonia cases diagnosed based on urinary pneumococcal antigen tests or Gram staining at admission. The efficacy of high-dose penicillin therapy for pneumococcal pneumonia diagnosed based on an initial comprehensive assessment comprising a syndromic approach, Gram staining of sputum and urinary pneumococcal antigen testing was investigated.
Introduction
In initial assessments of pneumonia cases, it is often difficult to identify the causative organism based on clinical presentation and microbial examination [1] [2] [3] [4] [5] [6] [7] [8] , and most pneumonia guidelines thus recommend initial empirical treatment using broad-spectrum antibiotics [9, 10] . However, previous randomized controlled trials have shown that pathogen-directed antibiotic therapy using narrowspectrum antibiotics is as effective as empirical antibiotic therapy for community-acquired pneumonia (CAP) [11, 12] . Given that adverse drug events occur more frequently with empirical treatment than with pathogendirected therapy [11, 13] , the latter may be preferred.
Streptococcus pneumoniae is the most common causative organism of CAP requiring hospitalization in adults [14, 15] . Previous studies have reported high treatment success rates with high-dose penicillins or amoxicillin for pneumococcal pneumonia diagnosed based on either urinary pneumococcal antigen test [16, 17] or Gram staining of sputum [13] at admission. However, little is known about the efficacy of strategies to diagnose pneumococcal pneumonia based on an initial comprehensive assessment combining clinical history, Gram staining of sputum and the urinary pneumococcal antigen test followed by treatment with high-dose penicillins as an initial monotherapy. Thus, the aim of this research was to evaluate the efficacy of high-dose penicillin G for pneumococcal pneumonia diagnosed based on an initial comprehensive assessment at admission.
Main text

Methods
Study design and setting
This study was a retrospective observational study utilizing data obtained from electronic medical records of the National Hospital Organization Tochigi Medical Center, a 350-bed acute-care hospital in Japan. At that time, this hospital did not have an intensive care unit. This research was retrospectively registered as UMIN000025887 (January 28, 2017).
Participants and inclusion criteria
Patients aged 18 years or older who were admitted to the hospital for pneumonia and initially treated with high-dose penicillin G from April 2012 to May 2017 were included. During the study period, 78 patients who had received high-dose penicillin G treatment for pneumonia were identified. Among them, eight patients did not initially receive penicillin G treatment on the day of admission. Overall, 70 patients were included in the final analysis.
Initial comprehensive assessment and treatment
Beginning in April 2012, the hospital started pathogen-targeted therapy for hospitalized adult pneumonia patients in routine practice. When pneumonia is diagnosed by medical history, a physical examination, and a chest X-ray, expectorated sputum samples are collected by a nurse before administering antibiotics. If possible, physicians or laboratory technicians then perform and interpret sputum Gram staining at admission. Only good-quality sputum is used to determine the causative pathogen, although sputum quality is rather subjective and at the discretion of the principal physicians. When S. pneumoniae is clinically suspected to be the causative organism of pneumonia at the initial assessment, physicians perform urine antigen testing for S. pneumoniae. The physicians also prescribe either high-dose penicillin G or ampicillin at their discretion if one of the following is present: (1) gram-positive diplococci upon Gram staining; (2) positive urine antigen test; (3) sudden onset of fever, chest pain, lobar infiltrate, and leukocytosis at presentation (syndromic approach). Our syndromic approach is similar to a strategy used by a pathogen-directed therapy group in a previous study [11] . Patients who were treated with ampicillin based on the initial comprehensive assessment at admission were excluded because ampicillin is often prescribed empirically for aspiration pneumonia in this hospital.
Microbiological investigations
In routine practice, physicians perform sputum Gram staining and establish a sputum culture when possible at admission; during the diagnostic process, physicians also establish at least two sets of blood cultures. When S. pneumonia is clinically suspected to be the causative organism of pneumonia, physicians perform urine antigen tests using the BinaxNOW S. pneumoniae urinary antigen kit (Alere Scarborough, Inc. Scarborough, USA). The proportion of patients who were evaluated using these tests is shown in Additional file 1. The definitions of sputum quality for Gram staining, predominant morphotype, and etiology of pneumonia are also shown in Additional file 2.
Data collection and measurement
Information on age, gender, symptoms, swallowing problems, past medical history, results of laboratory testing, and chest radiographs was retrieved from electronic medical records at admission. The pneumonia severity index (PSI) [18] and CURB-65 score [9, 19] at admission were calculated.
The primary outcome was the treatment success rate. Based on a previous study [12] , treatment was judged to be successful when clinical stability was achieved between 2 and 6 days after admission (detailed information is provided in Additional file 2). Secondary outcomes included in-hospital mortality, 30-day mortality, 30-day readmission rate, and adverse drug events caused by penicillin G. Adverse drug events were determined based on documented physician diagnosis in medical records. The rate of change in the use of other intravenous antibiotics due to a lack of effectiveness against pneumonia was also assessed, as the clinical stability of pneumonia patients based on vital signs can be delayed, even if treatment is effective [20] . The last follow-up date was May 31, 2017.
Statistical analysis
Originally, this study was planned to target 100 patients, a size similar to pathogen-targeted therapy groups in previous randomized controlled trials [11, 12] . However, penicillin G use for pneumococcal pneumonia at this hospital has declined since 2015, partly because ampicillin was more frequently selected as an initial antibiotic agent for pneumococcal pneumonia due to the inconvenience of prescribing penicillin G. Therefore, the outcomes of 70 patients were analyzed.
Baseline characteristics were examined using descriptive statistics. Primary and secondary outcomes were calculated as the proportion of patients in whom those outcomes occurred in all patients. The Chi squared test was used to compare primary outcomes between subgroups of patients for whom pneumonia severity was classified based on PSI or CURB-65. The Chi squared test was also used for comparison of primary outcomes between pneumococcal pneumonia and pneumonia of undetermined etiology based on microbial investigation. Given that S. pneumoniae is the leading cause of pneumonia of unknown etiology [21, 22] , a similar efficacy of treatment between each subgroup was hypothesized. These analyses were performed using Excel statistical software package version 2.11 (Bellcurve for Excel; Social Survey Research Information Co., Ltd., Tokyo, Japan); the level of significance was set at 5%.
Results
The baseline characteristics of the patients are presented in Table 1 . The median age of the 70 patients was 76.5 years, and 26 (37.1%) were women. The median PSI score of the pneumonia cases was 97.5 ( Table 2 ).
In the initial assessment, the urinary pneumococcal antigen test was positive in 47 (67.1%) of the 70 patients, and gram-positive cocci (GPC) were dominant upon Gram staining of sputum samples from 41 patients (58.6%). Regarding the etiology of pneumonia based on the final results of microbial investigation, 46 cases (65.7%) were Streptococcus pneumoniae, and 17 (24.3%) were of an undetermined etiology. Among the 46 cases of presumed pneumococcal pneumonia, penicillin-susceptible S. pneumoniae (PSSP) and penicillin-intermediate resistant S. pneumoniae (PISP) were isolated from 20 patients and one patient, respectively. Penicillin-resistant S. pneumoniae (PRSP) was not isolated from any patient.
The treatment success rate was 87.1% ( Table 3 ). The proportion of patients who were switched from penicillin G to other antibiotics due to pneumonia treatment failure (detailed information is described in an Additional file 2) was only 5.7%. Two patients died in the hospital. During the study period, no drug adverse events caused by penicillin G were documented. However, in one patient, penicillin G was replaced by high-dose ampicillin because continuous infusion of penicillin G was judged by the principal physician to be difficult due to delirium. The treatment success rate did not differ significantly among the subgroups of patients classified according to pneumonia severity and was not different between pneumococcal pneumonia and pneumonia of undetermined etiology based on the final results of microbial investigations (detailed information is described in an Additional file 1). 
Discussion
The results of this study showed that treatment with high-dose penicillin G for pneumococcal pneumonia diagnosed based on a comprehensive initial assessment using a syndromic approach, Gram staining of sputum, and the urinary pneumococcal antigen test was effective in 87% of all cases. The results of the present study are similar to those of past studies, showing that pathogendirected therapy [11-13, 16, 17] or empirical therapy with broad-spectrum antibiotic agents [11, 12, [20] [21] [22] [23] [24] [25] is effective in 80-90% of CAP patients, even though the definition of treatment success differed somewhat from those of past studies [26] . Furthermore, adverse drug events in the present study were less frequent than in past studies that investigated the efficacy of broad-spectrum antibiotic agents for CAP patients [11, 12, [22] [23] [24] [25] .
Given that sputum specimens of high quality are not often obtained [14] and that the sensitivity of the urinary pneumococcal antigen test for diagnosis of pneumococcal pneumonia is inadequate [4] , these findings are notable. Furthermore, this strategy may be preferable because drug adverse events occur in empirical therapy more frequently than in pathogen-targeted therapy [11, 13] . Nonetheless, these findings should be interpreted with caution given that this study lacked a control group, which is a major limitation. Although the baseline patient characteristics and the severity of pneumonias in the present study were not different from those in past studies of CAP [11-13, 16, 17, 20-25] , the lack of a control group may confound the outcomes. Furthermore, the 95% confidence interval for the primary outcome was wide due to the small sample size, and its lower limit was less than 80%. This efficacy rate might be unacceptable. Therefore, a well-designed study is needed to evaluate the efficacy of this strategy for pneumonia patients.
The efficacy of high-dose penicillin G therapy did not differ between pneumococcal pneumonia and pneumonia of undetermined etiology based on the final results of the microbial investigations. Given that penicillin G is a narrow-spectrum antibiotic agent, this finding supports past studies showing that S. pneumoniae is the leading cause of pneumonia of unknown etiology [27, 28] , although some cases of pneumonia of undetermined etiology in this study might have been caused by viral infection [29] .
De-escalation therapy after initial empirical therapy is uncommon in practice due to the undetermined etiology in most pneumonia patients [14] . Furthermore, relative to the practice of treating pneumonia patients with empirical antibiotic therapy, residents should be educated in the practice of estimating the suspected causative pathogen using clinical history and microbial tests [30, 31] . Therefore, further studies are warranted to identify an effective strategy for estimating the causative organism of pneumonia at an initial assessment and to treat the causative organism with narrow-spectrum antibiotic agents.
Conclusions
The efficacy of high-dose penicillin G therapy for pneumococcal pneumonia diagnosed based on a comprehensive assessment at admission may be acceptable. Nonetheless, the results of this study should be interpreted with caution due to the lack of a control group. A well-designed study is needed to evaluate the efficacy of this strategy for pneumonia patients.
Limitations
First, this study had a retrospective observational design. Second, this study was limited to a single center and to hospitalized patients receiving high-dose penicillin G therapy at admission; thus, the results may not be easily generalizable. These findings should be confirmed by future studies performed at other institutions. Third, it was unclear how often patients who were initially diagnosed with pneumococcal pneumonia at admission were treated with other antibiotic agents, such as ampicillin and ceftriaxone. It was also unclear whether the physicians prescribed penicillin G for pneumonia patients at admission because they truly suspected pneumococcal pneumonia. Fourth, PRSP was rarely isolated in this hospital. Therefore, these results may not be generalizable to other hospitals in which PRSP is more prevalent. Fifth, it is inconvenient to administer penicillin G via intravenous infusion, and high-dose ampicillin might be preferable as an initial antibiotic agent for pneumococcal pneumonia. Sixth, the study hospital does not have an intensive care unit. Therefore, these findings might not be applicable to cases of very severe pneumococcal pneumonia. Seventh, data were collected from usual care. Given that adverse drug events are often unrecognized by physicians [32] , these outcomes might be underestimated. Finally, a statistical analysis to investigate predictive factors associated with treatment success was not conducted. Authors' contributions JK designed the study, collected and analyzed the data, and wrote the main paper. The author read and approved the final manuscript. 
